NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD. Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Stock
Equities
603707
CNE100002WP3
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.69 CNY | -0.15% |
|
-0.07% | -8.73% |
| May. 01 | NKFPharma Gets Nod to Register New Cancer Treatment | MT |
| Apr. 27 | Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.37B 605M | Sales 2025 * | 6.07B 840M | Capitalization | 22.06B 3.05B |
|---|---|---|---|---|---|
| Net income 2024 * | 923M 128M | Net income 2025 * | 1.54B 214M | EV / Sales 2024 * | 5.04 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.63 x |
| P/E ratio 2024 * |
24
x | P/E ratio 2025 * |
14.3
x | Employees | 1,451 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 26.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.15% | ||
| 1 week | -0.07% | ||
| Current month | -0.07% | ||
| 1 month | +11.12% | ||
| 3 months | -4.93% | ||
| 6 months | +10.40% | ||
| Current year | -8.73% |
1 week
13.52
13.93
1 month
11.9713.93
Current year
10.7515.38
1 year
10.7516.40
3 years
10.7534.60
5 years
10.1335.52
10 years
2.8035.52
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Qun Tang
CEO | Chief Executive Officer | 49 | 03-12-31 |
Xiao Jie Qian
DFI | Director of Finance/CFO | 44 | 10-12-31 |
Xi Wei Huang
BRD | Director/Board Member | 54 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xi Wei Huang
BRD | Director/Board Member | 54 | 11-03-31 |
Ping Shi
BRD | Director/Board Member | 62 | 19-05-15 |
Yong Qun Tang
CEO | Chief Executive Officer | 49 | 03-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.49% | 0 M€ | -12.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 13.69 | -0.15% | 4,766,766 |
| 24-05-06 | 13.71 | +0.07% | 7,698,291 |
| 24-04-30 | 13.7 | +5.14% | 15,015,280 |
End-of-day quote Shanghai S.E., May 06, 2024
More quotes
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.
Sector
Pharmaceuticals
Calendar
2024-05-17
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.69
CNY
Average target price
16.32
CNY
Spread / Average Target
+19.17%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.73% | 3.06B | |
| +33.43% | 700B | |
| +26.43% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +14.32% | 236B | |
| +5.79% | 202B | |
| -9.49% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- 603707 Stock